全文获取类型
收费全文 | 39396篇 |
免费 | 3954篇 |
国内免费 | 2954篇 |
专业分类
耳鼻咽喉 | 293篇 |
儿科学 | 504篇 |
妇产科学 | 533篇 |
基础医学 | 4413篇 |
口腔科学 | 661篇 |
临床医学 | 5216篇 |
内科学 | 5949篇 |
皮肤病学 | 359篇 |
神经病学 | 1913篇 |
特种医学 | 1615篇 |
外国民族医学 | 12篇 |
外科学 | 4173篇 |
综合类 | 6722篇 |
现状与发展 | 6篇 |
一般理论 | 4篇 |
预防医学 | 2832篇 |
眼科学 | 921篇 |
药学 | 4162篇 |
38篇 | |
中国医学 | 2410篇 |
肿瘤学 | 3568篇 |
出版年
2024年 | 136篇 |
2023年 | 633篇 |
2022年 | 1569篇 |
2021年 | 1934篇 |
2020年 | 1490篇 |
2019年 | 1289篇 |
2018年 | 1345篇 |
2017年 | 1282篇 |
2016年 | 1248篇 |
2015年 | 1833篇 |
2014年 | 2198篇 |
2013年 | 1994篇 |
2012年 | 2706篇 |
2011年 | 3146篇 |
2010年 | 2084篇 |
2009年 | 1595篇 |
2008年 | 2056篇 |
2007年 | 2142篇 |
2006年 | 2050篇 |
2005年 | 1935篇 |
2004年 | 1445篇 |
2003年 | 1482篇 |
2002年 | 1262篇 |
2001年 | 1110篇 |
2000年 | 1024篇 |
1999年 | 929篇 |
1998年 | 584篇 |
1997年 | 622篇 |
1996年 | 420篇 |
1995年 | 369篇 |
1994年 | 306篇 |
1993年 | 228篇 |
1992年 | 275篇 |
1991年 | 259篇 |
1990年 | 232篇 |
1989年 | 200篇 |
1988年 | 165篇 |
1987年 | 159篇 |
1986年 | 134篇 |
1985年 | 85篇 |
1984年 | 53篇 |
1983年 | 30篇 |
1982年 | 16篇 |
1981年 | 17篇 |
1980年 | 27篇 |
1979年 | 46篇 |
1978年 | 22篇 |
1976年 | 12篇 |
1975年 | 18篇 |
1974年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
4.
5.
6.
7.
8.
Haochu Li Xiaoming Li Lai Sze Tso Shan Qiao Eleanor Holroyd Yuejiao Zhou 《Vulnerable children and youth studies》2016,11(2):173-179
In HIV/AIDS research, few studies to date have evaluated ways to improve parental HIV disclosure practices using feedback from HIV-negative children who have recently experienced this event. We conducted semi-structured in-depth interviews with 20 children (aged 6–15) who were partially to fully aware of their parents’ HIV status in rural Guangxi, China. Of the 20 children, eight children who were of older age (11.38 years in average) endorsed parental HIV disclosure, five discouraged it and seven expressed uncertainty. Children’s different experiences and attitudes towards disclosure were seen to be associated with their family dynamics (especially the parent–child relationship), social support and care, experiences of stigma and discrimination, psychosocial suffering, comprehension of the disease and the children’s age. Our study contributes to building a child-centered comprehensive understanding for Chinese parental HIV disclosure. It is imperative that counselors and community advocates assess and help parents achieve optimal readiness preceding disclosure of their illness to their HIV-negative children. 相似文献
9.
Xiaojie Wu Leyan Zhang Jiadi Zhou Luying Liu Qiang Fu Aili Fu Xiaoying Feng Rui Xin Hongrui Liu Yong Gao Jiangnan Xue 《Current problems in cancer》2019,43(1):18-26
Aim
Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an immune inhibitory receptor which is expressed within most types of hematopoietic cells and negatively regulates immune responses. Recently, we found LAIR-1 expression to be present within tumors of nonhematopoietic lineages. However, the roles of LAIR-1 in hepatocellular carcinoma (HCC) have yet to be examined. The purpose of this study was to investigate the expression of LAIR-1 in HCC tissue and assess its clinical significance at this site.Materials and methods
Expression levels of LAIR-1 within HCC samples collected from 90 patients and compared with that of slides of normal liver tissue collected from 9 non-HCC patients were measured by immunohistochemistry using tissue microarrays. A semiquantitative score was assigned, as was based on staining intensity and percent of positive cells and a Spearman Rank correlation test was used to assess any potential significant correlations between LAIR-1 expression and clinicopathological factors. Overall survival analysis was performed using the Kaplan-Meier and Log Rank statistical test.Results
LAIR-1 expression was detected in cancer tissue and adjacent tumor tissue, but not in normal liver tissue. The percent of LAIR-1-positive expression in cancer tissue of HCC samples was 97.78% (88/90) while that in adjacent tumor tissue was 96.67% (87/90). Significantly greater expression levels of LAIR-1 were obtained from cancer tissue (Mean?±?SD?=?5.722?±?2.145) than that in adjacent tumor tissue (4.141?±?1.486). In addition, LAIR-1 expression was found to be significantly correlated with pathological grade of HCC, T stage, and age. Expression levels of LAIR-1 were related with worse overall survival rates of HCC patients, especially in HCC patients with hepatic cirrhosis.Conclusion
Results of this study show that LAIR-1 is expressed in HCC tissues and that high levels of LAIR-1 expression are associated with the poor cancer differentiation. In addition, overexpression of LAIR-1 was significantly associated with worse overall survival in the patients with HCC. These data suggest that LAIR-1 may be an independent predictor for clinical outcomes in patients with HCC. 相似文献10.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801